Product news from the 12/12/06 news brief

Share this article:
Millennium Pharmaceuticals received FDA approval to market Velcade for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. MCL is a relatively uncommon and aggressive form of non-Hodgkin's lymphoma for which there was no standard of care in the relapsed or refractory setting. MCL has a US prevalence of 10,000 patients. Velcade is currently the market leader in multiple myeloma for patients who have received one prior therapy.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions